GSK Regulatory Update: Avodart

GSK announced today that in order to provide an update to the application, the company is withdrawing its US sNDA for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease. GSK expects to resubmit the file shortly. This action is not the result of new findings related to safety or efficacy.